[Gene therapy of melanoma: review of published clinical trials].
BACKGROUND
Melanoma frequency increases. Conventional antitumoral treatments fail. Gene therapy for metastatic melanoma is studied in 17 phase I-II clinical trials. ACTUALITES ET POINTS FORTS: Sixteen use cytokine genes. These studies are heterogenous as far as methodology is concerned. Gene therapy clinical tolerance is acceptable. Security is rarely discuted. In these studies overall response rate is 8%, with histological complete responses.


CONCLUSIONS
Presently, three new studies are opened in United States.
Penel
N
N
Département de cancérologie générale, centre Oscar-Lambret, 3, rue F.-Combemale, 59020 cedex, Lille, France. n-penel@o-lambert.fr <n-penel@o-lambert.fr>
Bonneterre
J
J
D002986:Clinical Trials as Topic; D016207:Cytokines / Q000235:genetics*; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000235:genetics* / Q000628:therapy*; D016896:Treatment Outcome
D016207:Cytokines